Biofunctional alendronate-Hydroxyapatite thin films deposited by Matrix Assisted Pulsed Laser Evaporation

被引:60
作者
Bigi, Adriana [1 ]
Boanini, Elisa [1 ]
Capuccini, Chiara [1 ]
Fini, Milena [2 ]
Mihailescu, Ion N. [3 ]
Ristoscu, Carmen [3 ]
Sima, Felix [3 ]
Torricelli, Paola [2 ]
机构
[1] Univ Bologna, Dept Chem G Ciamician, I-40126 Bologna, Italy
[2] Rizzoli Orthopaed Inst, Res Inst Codivilla Putti, Lab Preclin Surg Studies, Bologna, Italy
[3] Natl Inst Lasers Plasma & Radiat Phys, Bucharest 77125, Romania
关键词
Bisphosphonate; Alendronate-doped hydroxyapatite films; MAPLE; Osteoblast; Osteoclast; IN-VITRO; OSTEOBLAST; BISPHOSPHONATES; OSTEOCLASTS; EXPRESSION;
D O I
10.1016/j.biomaterials.2009.07.066
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
We applied Matrix Assisted Pulsed Laser Evaporation (MAPLE) in order to synthesize alendronate-hydroxyapatite thin films on titanium substrates. Alendronate-hydroxyrapatite composite nanocrystals with increasing bisphosphonate content (0, 3.9, 7.1%wt) were synthesized in aqueous medium. Then, they were suspended in deionised water, frozen at liquid nitrogen temperature and used as targets for MAPLE experiments. The depositions were conducted with a KrF* excimer laser source (1 = 248 turn, t(FWHM) = 25 ns) in mild conditions of temperature and pressure. The obtained thin films had a good crystallinity, which slightly decreases with the increase of alendronate content, and exhibited a porous-like structure. Osteoblast-like MG63 cells and human osteoclasts were cultured on the thin films up to 14 days. In the presence of alendronate, MG63 cells displayed a normal morphology, increased proliferation and higher values of differentiation parameters, namely type I collagen, osteocalcin, and osteoprotegerin/TNF-related activation-induced cytokine receptor ratio. In contrast, osteoclasts showed significantly reduced proliferation, and increased level of Caspase 3. Moreover, the coatings synthesized from hydroxyapatite at relatively high bisphosphonate content (7.1% wt) displayed a reduced production of Tumour Necrosis Factor alpha (TNF-alpha) and Interleukin 6 (IL-6), suggesting a down-regulatory role of alendronate on the inflammatory reaction. The successful deposition of alendronate modified hydroxyapatite thin films yields coatings with enhanced bioactivity, able to promote osteoblast differentiation and to inhibit osteoclast proliferation. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6168 / 6177
页数:10
相关论文
共 34 条
[1]   Bisphosphonate antifracture efficacy [J].
Adami, Silvano .
BONE, 2007, 41 (05) :S8-S15
[2]   Osteoblast adhesion on biomaterials [J].
Anselme, K .
BIOMATERIALS, 2000, 21 (07) :667-681
[3]   Human osteoblast response to pulsed laser deposited calcium phosphate coatings [J].
Bigi, A ;
Bracci, B ;
Cuisinier, F ;
Elkaim, R ;
Fini, M ;
Mayer, I ;
Mihailescu, IN ;
Socol, G ;
Sturba, L ;
Torricelli, P .
BIOMATERIALS, 2005, 26 (15) :2381-2389
[4]   Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells [J].
Boanini, Elisa ;
Torricelli, Paola ;
Gazzano, Massimo ;
Giardino, Roberto ;
Bigi, Adriana .
BIOMATERIALS, 2008, 29 (07) :790-796
[5]   Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure [J].
Boanini, Elisa ;
Gazzano, Massimo ;
Rubini, Katia ;
Bigi, Adriana .
ADVANCED MATERIALS, 2007, 19 (18) :2499-+
[6]   The effect of the matrix on film properties in matrix-assisted pulsed laser evaporation [J].
Bubb, DM ;
Wu, PK ;
Horwitz, JS ;
Callahan, JH ;
Galicia, M ;
Vertes, A ;
McGill, RA ;
Houser, EJ ;
Ringeisen, BR ;
Chrisey, DB .
JOURNAL OF APPLIED PHYSICS, 2002, 91 (04) :2055-2058
[7]   Strontium-substituted hydroxyapatite coatings synthesized by pulsed-laser deposition: In vitro osteoblast and osteoclast response [J].
Capuccini, C. ;
Torricelli, P. ;
Sima, F. ;
Boanini, E. ;
Ristoscu, C. ;
Bracci, B. ;
Socol, G. ;
Fini, M. ;
Mihailescu, I. N. ;
Bigi, A. .
ACTA BIOMATERIALIA, 2008, 4 (06) :1885-1893
[8]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249
[9]  
Fleisch H., 2000, Bisphosphonates in bone disease: From the laboratory to the patient
[10]  
Giordano C, 2004, J Appl Biomater Biomech, V2, P35